New cocktail aims to outsmart Drug-Resistant liver cancer
NCT ID NCT07324473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—ivarmacitinib, camrelizumab, and apatinib—in 65 people with advanced liver cancer that has stopped responding to initial immunotherapy. The goal is to see if this triple therapy can shrink tumors or slow disease progression. Participants will receive the drugs for up to 2 years, with regular imaging scans to track results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivarmacitinib, Camrelizumab, and Apatinib
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced liver cancer whose tumors have stopped responding to standard immunotherapy.
- What could go wrong
- This is an early Phase 2 study with only 65 people, so results may not apply to everyone. The triple-drug combination also carries risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG REPURPOSING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.